Crisis Management in Systemic Lupus Erythematosus

Initial Therapy

The European League Against Rheumatism recommends adding cyclophosphamide and/or intravenous immunoglobulin and/or therapeutic plasma exchange and/or rituximab to high-dose glucocorticoids for patients with diffuse alveolar hemorrhage, as no single agent is prioritized over another given the high mortality rate and lack of comparative evidence 1, 2
The European League Against Rheumatism suggests that cost and availability typically favor glucocorticoids plus cyclophosphamide as the most practical combination for patients with diffuse alveolar hemorrhage 1, 2

The European League Against Rheumatism recommends adding cyclophosphamide to glucocorticoids for patients with severe acute neurologic manifestations, such as seizures, psychosis, myelitis, peripheral neuropathy, brain stem disease, or optic neuritis 1, 2
The European League Against Rheumatism suggests that rituximab is an alternative for patients with severe acute neurologic manifestations, but has lower quality evidence and was only evaluated in refractory patients 1, 2
The European League Against Rheumatism favors cyclophosphamide due to better certainty of evidence and lower cost for patients with severe acute neurologic manifestations 1, 2
The European League Against Rheumatism recommends adding either mycophenolate mofetil or low-dose IV cyclophosphamide to high-dose glucocorticoids for patients with lupus nephritis crisis (Class III-IV) 1, 2
The European League Against Rheumatism suggests that high-dose glucocorticoids alone are first-line therapy for patients with severe hemolytic anemia (hemoglobin ≤8 g/dL) 1, 2
The European League Against Rheumatism recommends reserving rituximab for refractory cases of severe hemolytic anemia, as it increases infection risk and has cost/availability concerns 1, 2

The European League Against Rheumatism advises against using prednisone >1 mg/kg/day or >60 mg/day, as higher doses do not improve outcomes and accelerate damage accrual 1, 2
The European League Against Rheumatism recommends avoiding delayed immunosuppressive therapy, as glucocorticoids alone are insufficient for crisis management and lead to prolonged high-dose steroid exposure 1, 2
The European League Against Rheumatism suggests considering gonadal toxicity when using cyclophosphamide in reproductive-age patients and counseling about fertility preservation options 1, 2

The European League Against Rheumatism recommends immediately administering intravenous methylprednisolone pulse therapy (250-1000 mg daily for 1-3 days) to provide rapid therapeutic effect, followed by oral glucocorticoids at doses determined by organ involvement severity 3
Life-threatening organ involvement, such as renal, neuropsychiatric, or cardiopulmonary manifestations, requires immediate attention and treatment, according to the American College of Rheumatology 3, 4

For life-threatening or organ-threatening disease, the American College of Rheumatology recommends initiating pulse intravenous methylprednisolone (usually 250-1000 mg per day for 1-3 days) and following with oral prednisone 0.5-1 mg/kg/day depending on severity 3, 4
The European League Against Rheumatism suggests adding immunosuppressive agents (cyclophosphamide, mycophenolate, or azathioprine) to expedite glucocorticoid tapering 3, 4

The American College of Rheumatology recommends maintaining a high index of suspicion for infection in immunosuppressed patients and obtaining cultures before initiating immunosuppression when infection cannot be excluded 5
All patients with systemic lupus erythematosus should receive hydroxychloroquine unless contraindicated, as it reduces flares, increases remission rates, and improves survival even in severe disease, according to the European League Against Rheumatism 4, 6

After initial emergency period (48-72 hours), the American College of Rheumatology recommends aggressively tapering oral prednisone with a goal of <7.5 mg/day for maintenance and ensuring immunosuppressive agents are initiated to enable glucocorticoid withdrawal 3, 4

The European League Against Rheumatism recommends ruling out infection first in all immunosuppressed patients before escalating immunosuppression, as SLE patients have a 5-fold increased mortality risk with infections being a leading cause 7
The American College of Rheumatology suggests adding cyclophosphamide to high-dose glucocorticoids as first-line therapy for severe acute neurologic manifestations, with response rates of 18/19 patients versus 7/13 with methylprednisolone alone (p=0.03) 8
For acute confusional state, extensively evaluate for infections and metabolic disturbances with CSF examination to exclude CNS infection, EEG to diagnose seizures, and brain imaging if focal signs present, as recommended by the European League Against Rheumatism 8
For lupus psychosis, combination of glucocorticoids and cyclophosphamide results in 60-80% response, though relapses occur in up to 50% of cases, according to the American College of Rheumatology 8
For myelopathy, contrast-enhanced spinal cord MRI is mandatory to detect T2-weighted hyperintense lesions (70-93% sensitivity), and treatment with IV methylprednisolone plus IV cyclophosphamide must be given within the first few hours for optimal neurological recovery, as suggested by the European League Against Rheumatism 8

The American College of Rheumatology recommends using validated activity indices (BILAG, ECLAM, or SLEDAI) to track response, and screening for treatment complications including infections, osteoporosis, cardiovascular disease, and malignancies (especially non-Hodgkin lymphoma) 7